US appeals court halts mail delivery of abortion pill

In a significant legal development, a US appeals court has issued a temporary halt to the mail delivery of mifepristone, the medication central to a majority of abortions performed in the United States. This decision stems from a lawsuit initiated by Louisiana, a state known for its stringent anti-abortion laws, challenging the Food and Drug Administration's regulations.

“

Victory for Life!

The three-judge panel's order mandates that individuals seeking abortions must now obtain mifepristone in person from health clinics, effectively banning its delivery via mail or through pharmacies. This move directly contradicts the FDA's previous approvals and has been met with strong reactions from both sides of the abortion debate.

Danco Laboratories, a primary distributor of the drug, has announced its intention to seek an emergency review from the US Supreme Court, requesting a one-week pause on the appeals court's order to prepare its case. This legal battle highlights the ongoing and deeply divisive nature of abortion access in the United States, with the courts becoming a key battleground.

“

The Biden abortion cartel facilitated the deaths of thousands of Louisiana babies (and millions in other states) through illegal mail-order abortion pills. Today, that nightmare is over.

Supporters of the ruling, like Louisiana Attorney General Liz Murrill, have hailed it as a "Victory for Life!" Murrill accused the "Biden abortion cartel" of facilitating abortions through mail-order pills. Conversely, opponents, such as Nancy Northup, president and CEO of the Centre for Reproductive Rights, condemned the decision, stating, "This isn’t about science — it’s about making abortion as difficult, expensive, and unreachable as possible." The ACLU's Julia Kaye echoed this sentiment, suggesting that "anti-abortion politicians" are behind the move.

“

This isn’t about science — it’s about making abortion as difficult, expensive, and unreachable as possible.

The appeals court's decision overturned a lower court's ruling that had permitted mail delivery while the FDA reviewed the drug's safety. The debate over mifepristone's safety has been fueled by studies, including one not peer-reviewed and published by a conservative think-tank. The FDA first approved mifepristone in 2000, and it remains the most common method for early-term abortions and is also used for managing miscarriages.

“

Danco requests a temporary administrative stay of the Panel’s Order for one week… to allow Danco time in which to seek relief in the United States Supreme Court.